arrow
A

Arne Kandulski

University Hospital Regensburg
H指数:29
被引数:3,586

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Study protocol of a prospective, non-interventional cohort study evaluating the benefits of transjugular intrahepatic portosystemic shunt in patients with hepatocellular carcinoma receiving first-line atezolizumab plus bevacizumab (NISTIPS TRITICC-4, IKF092)

前瞻性、非干预性队列研究方案:评估经颈静脉肝内门体分流术在初次接受阿替利珠单抗联合贝伐珠单抗治疗的肝细胞癌患者中的获益(NISTIPS TRITICC-4,IKF092)

2026-10-200
OA
Artificial intelligence-assisted detection and optical differentiation of colorectal lesions in Lynch syndrome surveillance (CADLY2): a multicentre, open-label, randomised controlled superiority trial

人工智能辅助的结直肠病变检测和光学鉴别在林奇综合征筛查中的应用(CADLY2):一项多中心、开放标签、随机对照优效性试验

2026-07-160
OAAI
Reciprocal Serum Phosphatidylcholine Signatures Are Related to Intestinal Inflammation in Inflammatory Bowel Disease and Liver Fibrosis in Primary Sclerosing Cholangitis—An Exploratory Study

血清磷脂酰胆碱特征与炎症性肠病中的肠道炎症和原发性硬化性胆管炎中的肝纤维化相关——一项探索性研究

2026-07-020
OAAI
Supplementary biomarker testing in molecular tumor boards increases actionable therapy recommendations: a prospective real-world study of 658 patients

补充生物标志物检测在分子肿瘤委员会中增加了可操作的治疗建议:一项包含658名患者的前瞻性真实世界研究

2026-01-140
OAAI
Mucosal calprotectin associates with severity of aGI-GvHD and poor outcomes after allogeneic stem cell transplantation

黏膜钙卫蛋白与aGI-GvHD的严重程度及异基因干细胞移植后的不良结局相关

Blood
IF23.1
2025-10-060
PRE
Cholesteryl Ester Species but Not Serum Proprotein Convertase Subtilisin/Kexin Type 9 Levels Decline in Male Patients with Active Inflammatory Bowel Disease

胆固醇酯种类在活动性炎症性肠病男性患者中下降,但血清前蛋白转化酶枯草溶菌素/克欣肽类型9水平未下降。

2025-10-020
OAAI
Protocol: Faecal microbiota transfer in liver cancer to overcome resistance to atezolizumab/bevacizumab - a multicentre, randomised, placebo-controlled, double-blind phase II trial (the FLORA trial)

方案:粪菌移植在肝癌中克服阿替利珠单抗/贝伐珠单抗耐药的多中心、随机、安慰剂对照、双盲II期试验(FLORA试验)

2025-09-090
OAAI
Therapeutic Sequences of Systemic Therapy After Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma: Real-World Analysis of the IMMUreal Cohort

阿特珠单抗联合贝伐单抗治疗后肝癌系统性治疗的后续治疗顺序:IMMUreal队列的真实世界分析

2025-04-040
OAAI
Atezolizumab/bevacizumab and lenvatinib for hepatocellular carcinoma: A comparative analysis in a European real-world cohort

阿特珠单抗/贝伐单抗和乐伐替尼治疗肝细胞癌: 欧洲真实世界队列的比较分析

2024-11-013
OAAI